This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors.
The “Berlin patient” was cured from HIV after getting new T-cells that did not have a coreceptor the HIV could bind to. The mechanism of action for this product is in principle the same – HIV will be unable to form a binding to the co-receptors CCR5 and CXCR4 and consequently cannot re-infect new T-cells.
This product will also cause a draining of the reservoirs by allowing the other vaccines to attack visible HIV infected T-cells. This property is unique to CRX and is in contrast to ART which hides the reservoirs and leave them intact and fit for new HIV production once ART is stopped.
Proof of Mechanism is established for CRX.
Patent application on CRX is filed.
Optimization of compounds, including formulation is currently ongoing.